Last reviewed · How we verify
NOVA22007
NOVA22007 is a selective antagonist of the neurokinin-1 (NK1) receptor that reduces neurogenic inflammation and pain signaling in the eye.
NOVA22007 is a selective antagonist of the neurokinin-1 (NK1) receptor that reduces neurogenic inflammation and pain signaling in the eye. Used for Dry eye disease (keratoconjunctivitis sicca), Ocular pain and inflammation.
At a glance
| Generic name | NOVA22007 |
|---|---|
| Sponsor | Santen SAS |
| Drug class | NK1 receptor antagonist |
| Target | NK1 receptor (neurokinin-1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
The drug blocks NK1 receptors, which are involved in pain transmission and inflammatory responses in ocular tissues. By inhibiting substance P signaling through NK1 receptors, NOVA22007 aims to reduce ocular pain and inflammation associated with dry eye disease and other anterior segment conditions.
Approved indications
- Dry eye disease (keratoconjunctivitis sicca)
- Ocular pain and inflammation
Common side effects
- Ocular irritation
- Conjunctival hyperemia
- Eye discomfort
Key clinical trials
- 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin) (PHASE3)
- Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis (PHASE3)
- Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC) (PHASE2, PHASE3)
- NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye (PHASE2)
- Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome (PHASE3)
- Cyclosporin A Eye Drop Treatment in Vernal Keratoconjunctivitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NOVA22007 CI brief — competitive landscape report
- NOVA22007 updates RSS · CI watch RSS
- Santen SAS portfolio CI